Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia

Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term post-vaccination side effects. Methods: Cross-section...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccines (Basel) Jg. 9; H. 6; S. 674
Hauptverfasser: Alhazmi, Abdulaziz, Alamer, Edrous, Daws, Dalia, Hakami, Mashael, Darraj, Majid, Abdelwahab, Siddig, Maghfuri, Amani, Algaissi, Abdullah
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Basel MDPI AG 18.06.2021
MDPI
Schlagworte:
Adenoviruses
Age
Chronic illnesses
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
Disease prevention
Drug dosages
Fatigue
FDA approval
Fever
Infections
mRNA vaccines
Pain
Pandemics
Population
Questionnaires
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Side effects
Social networks
vaccine
Vaccines
Saudi Arabia
United States > US
ISSN:2076-393X, 2076-393X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term post-vaccination side effects. Methods: Cross-sectional, retrospective study using an online questionnaire was conducted among COVID-19 vaccines recipients in Saudi Arabia. General and demographic data were collected, and vaccine-associated side effects after receiving at least one dose of each vaccine were evaluated. Results: Our final sample consisted of 515 participants with a median age of 26 years. Most of the study participants were female (57%). Nearly 13% of the study subjects have reported previous infections with SARS-CoV-2. Oxford-AstraZeneca and Pfizer-BioNTech vaccines have been received by 75% and 25% of the study participants, respectively. Side effects associated with COVID-19 vaccines have been reported by 60% of the study subjects, and most of them reported fatigue (90%), pain at the site of the injections (85%). Conclusion: Side effects that are reported post Oxford-AstraZeneca and Pfizer-BioNTech vaccines among our study participants are not different from those that were reported in the clinical trials, indicating safe profiles for both vaccines. Further studies are needed to evaluate the effectiveness of the current vaccines in protection against SARS-CoV-2 reinfections.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9060674